Shareholders meeting

Emcure Ref: EPL/CS/SE/0075/2026 Date: August 28, 2026 National Stock Exchange of India BSE Limited Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai- 400 001 Mumbai – 400 051 Scrip Code/Symbol: 544210/ EMCURE Script Symbol: EMCURE Dear Sir/Madam, Subject: Annual Report for the Financial Year 2025-26 and the Notice of the 45th Annual General Meeting of Emcure Pharmaceuticals Limited (‘the Company’) Pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Annual Report for the Financial Year 2025-26, including the Notice of the 45th Annual General Meeting (“AGM”), scheduled to be held on Monday, September 21, 2026, at 11.00 a.m. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”), without the physical presence of the Members at a common venue, in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. All the Members holding shares as on the cut-off date i.e. Monday, September 14, 2026, will be able to attend the AGM through VC/OAVM platform, provided by MUFG Intime India Private Limited (Formerly Link Intime India Private Limited). The Notice of the 45th AGM and Annual Report for the Financial Year 2025-26 is enclosed herewith and is also made available on the Company’s website at https://www.emcure.com/wp-content/uploads/2026/08/Annual-Report-FY-2025-26.pdf & on the website of MUFG Intime India Private Limited at https://in.mpms.mufg.com/. The information about remote e-voting is as follows: Timeline Remote e-voting Begins Friday, September 18, 2026 at 9:00 a.m. (IST) Remote e-voting Ends Sunday, September 20, 2026 at 5:00 p.m. (IST) You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Pharmaceuticals Limited Annual Report 2025-26 Complex Science Disciplined Execution Compounding Value C O N T E N T S 01 Corporate 02 Statutory overview reports 2 T he Three Pillars of Precision 73 Management Discussion 4 FY 2025-26 Highlights & Analysis 6 About the Report 84 Company Information 8 Chairman’s Message 85 Board’s Report 10 CEO’s Message 101 Corporate Governance 14 In Conversation with the CFO Report 18 Corporate Overview 134 Business Responsibility and 20 Our Journey Sustainability Report 22 Our Business Model 24 Our Strategic Priorities 03 Financial 26 Therapeutic Areas and Key statements Brands in Domestic Business 30 Domestic Business Performance 36 International Business 166 Standalone Financial 38 Europe Statements 40 Canada 259 Consolidated Financial 43 Rest of World (RoW) Statements 46 R&D Edge 50 Manufacturing Strength 56 Enterprise Risk Management 358 Notice 58 IT & Digital Transformation 62 People and Culture 66 Corporate Social Responsibility 68 Board of Directors 71 Leadership Team 72 Key Performance Indicators Emcure at a Glance INR 92,035 19.4% 80+ Revenue from operations EBITDA margin Countries #2 23.7% Rank in Gynaecology ROCE in India Forward-looking statement This Annual Report contains forward-looking statements relating to our business outlook, strategy, growth plans, product pipeline, financial performance and operating priorities. These statements are based on current assumptions, expectations and estimates, and are therefore subject to risks and uncertainties that could cause actual outcomes to differ materially. We do not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. Corporate Overview Complex Science Disciplined Execution Compounding Value Pharmaceutical growth becomes more meaningful when scientific capability meets execution discipline. That is the path we are continuing to build on, with strengths in complex chemistry, biologics and injectables helping us widen our portfolio and deepen our presence across India and international markets. A stronger domestic business, a more differentiated global portfolio and an innovation pipeline focussed on high-value opportunities are now reinforcing one another. Together, they are improving the quality of growth, strengthening resilience and creating a business that is scaling with greater purpose and compounding stakeholder value. Annual Report 2025-26 1 Emcure Pharmaceuticals Limited The Three Pillars of Precision 2 Annual Report 2025-26 Corporate Overview DOMESTIC GLOBAL SCALING INNOVATION DEEPENING Expanding our PIPELINE Strengthening our India international business Advancing an innovative business through deeper through differentiated pipeline to support future therapy presence, a higher product launches, stronger growth across markets. chronic mix, sharper front-end capabilities and FY 2026-27 priorities execution and targeted in- an improved market mix. licensing. FY 2026-27 priorities FY 2026-27 priorities Progress near-term Accelerate growth in assets across obesity, Expand scale in Canada and Europe ophthalmology, cardio-metabolic through in-house launches oncology, anti-infectives and women’s and inorganic expansion and HIV health segments Build new growth Expand RoW markets Continue investing areas including CNS, through biosimilars, complex in biologics, complex dermatology, onco injectables and non-ARV injectables, novel delivery and consumer health (Anti-retroviral) products platforms and antibody drug conjugates Annual Report 2025-26 3 Emcure Pharmaceuticals Limited FY 2025-26 Highlights F I N A N C I A L INR 92,035 INR 17,886 INR 9,413 Mn Mn Mn Revenue from operations EBITDA PAT ↑ 16.6% ↑ 21.8% ↑ 33.1% Y-o-Y Y-o-Y Y-o-Y 23.7% INR 3,835 INR 4,342 Mn Mn ROCE R&D Investments Capex Investment ↑ 170 4.2% ↑ 50 bps (Excluding Manx Acquisition) basis points of sales Y-o-Y E S G* 64.7% 11,686 INR 109 Renewable power in total Employees CSR spend energy mix Zero ~100 Mn+ 02/20% Cybersecurity Patients benefited Women representation on breaches the Board or threats reported Zero Zero Consumer complaints Cases of received on confirmed data privacy and corruption and cybersecurity bribery *All figures are as per the BRSR boundary except CSR and Employees which are at a consolidated level 4 Annual Report 2025-26 Corporate Overview O P E R A T I O N A L ~60%+ 32 INR 51,766 Chronic mix Large brands above INR 500 Mn International business revenue *Reclassifying ARV and Gynae ↑ 4x since 2020 ↑ 22.2% Y-o-Y Top 10 25+ 35+ Generic player in Canada New launches in the New launches in domestic market international markets Launched Liposomal Sanofi partnership Amphotericin B expanded A year Scaled up and secured approvals Expanded oral anti-diabetes for this complex injectable, brands to strengthen our of notable becoming the first generic entrant cardio-metabolics portfolio in Europe for this molecule firsts Roche partnership Europe platform signed strengthened Crossed USD 1 Bn in Strengthened our Expanded our product nephrology and transplant basket and market presence annual revenue, care portfolio with select through the Manx portfolio establishing Roche brands acquisition a new Novo Nordisk partnership R&D pipeline advanced operational Strengthened presence Progressed key scale in the metabolics therapy assets across obesity, through an exclusive ophthalmology, oncology, distribution arrangement anti-infectives and HIV Annual Report 2025-26 5 Emcure Pharmaceuticals Limited About the Report This Annual Report presents how we created value during FY 2025-26 through scientific capability, disciplined execution and strategic progre [Showing first 8,000 characters — download PDF for full document]